Onkure Therapeutics IncNASDAQ:OKUR
- LAST PRICE15.5500
- TODAY'S CHANGE (%)-0.4400 (-2.7517%)
- Bid / Lots14.1200/ 7
- Ask / Lots15.5500/ 9
- Open / Previous Close15.9400 / 15.9900
- Day Range
- 52 Week Range
- Volume53,091
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OKUR |
|---|---|---|
| 09:50 ET | 1166 | 16.1 |
| 10:11 ET | 100 | 16.11 |
| 10:18 ET | 500 | 16.01 |
| 10:24 ET | 100 | 15.859 |
| 10:36 ET | 135 | 15.855 |
| 10:42 ET | 100 | 15.99 |
| 10:49 ET | 500 | 15.87 |
| 11:00 ET | 300 | 15.98 |
| 11:09 ET | 197 | 15.97 |
| 11:12 ET | 1199 | 15.7512 |
| 11:21 ET | 166 | 15.66 |
| 11:32 ET | 100 | 16 |
| 11:34 ET | 2357 | 15.81 |
| 11:36 ET | 120 | 15.8501 |
| 11:39 ET | 100 | 15.99 |
| 12:28 ET | 100 | 16 |
| 12:32 ET | 388 | 15.96 |
| 12:46 ET | 1100 | 15.7515 |
| 12:53 ET | 1115 | 15.76 |
| 01:02 ET | 221 | 15.99 |
| 01:18 ET | 250 | 15.9513 |
| 01:20 ET | 100 | 15.97 |
| 01:24 ET | 160 | 15.93 |
| 01:26 ET | 100 | 15.93 |
| 01:47 ET | 1544 | 15.57 |
| 01:49 ET | 100 | 15.565 |
| 01:54 ET | 100 | 15.58 |
| 02:02 ET | 1210 | 15.55 |
| 02:12 ET | 695 | 15.5 |
| 02:18 ET | 10270 | 15.78 |
| 02:27 ET | 100 | 15.64 |
| 02:34 ET | 104 | 15.65 |
| 02:38 ET | 100 | 15.65 |
| 02:48 ET | 100 | 15.65 |
| 02:56 ET | 100 | 15.65 |
| 03:01 ET | 208 | 15.65 |
| 03:06 ET | 100 | 15.635 |
| 03:08 ET | 100 | 15.54 |
| 03:10 ET | 100 | 15.6 |
| 03:17 ET | 280 | 15.65 |
| 03:32 ET | 300 | 15.55 |
| 03:48 ET | 100 | 15.37 |
| 03:50 ET | 10701 | 15.55 |
| 03:53 ET | 403 | 15.53 |
| 04:00 ET | 2231 | 15.55 |
Nov 8, 2024
DJ OnKure Therapeutics Price Target Maintained With a $40.00/Share by HC Wainwright & Co., from 2:25PM ET on Friday Nov 08, 2024 by Dow Jones
2:25PM ET on Friday Nov 08, 2024 by Dow Jones
Nov 5, 2024
OnKure to Present at the Stifel 2024 Healthcare Conference, from 4:05PM ET on Tuesday Nov 05, 2024 by Dow Jones
4:05PM ET on Tuesday Nov 05, 2024 by Dow Jones
Nov 1, 2024
OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium, from 5:30PM ET on Friday Nov 01, 2024 by Dow Jones
5:30PM ET on Friday Nov 01, 2024 by Dow Jones
Oct 25, 2024
DJ VTv, OnKure Terminate Cellular Drug Licensing Agreement, from 5:41PM ET on Friday Oct 25, 2024 by Dow Jones
5:41PM ET on Friday Oct 25, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Onkure Therapeutics Inc | 213.3M | -1.3x | --- |
Trevi Therapeutics Inc | 209.8M | -6.6x | --- |
Solid Biosciences Inc | 209.0M | -1.8x | --- |
Lexeo Therapeutics Inc | 205.0M | -2.2x | --- |
Corbus Pharmaceuticals Holdings Inc | 203.8M | -3.7x | --- |
XBiotech Inc | 201.7M | -6.4x | --- |
Company Information
OnKure Therapeutics, Inc., formerly Reneo Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a robust pipeline of tumor-agnostic candidates. The Company is developing OKI-219, a selective PI3KαH1047R inhibitor, as its lead program. OKI-219 is being evaluated in a Phase I clinical trial in solid tumor patients with PI3KαH1047R mutations, including breast cancer. The Company is also focused on targeting oncogenic PI3Kα and has multiple programs designed to enable targeting of this key oncogene.
Contact Information
- Headquarters
- 6707 Winchester Circle, Suite 400BOULDER, CO, United States 80301
- Phone
- 720-307-2892
- Fax
- 302-674-5266
Executives
- Independent Chairman of the Board
- Andrew Philips
- President, Chief Executive Officer, Director
- Nicholas Saccomano
- Chief Financial Officer
- Jason Leverone
- Chief Scientific Officer
- Dylan Hartley
- Executive Director
- Michael Grey
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $213.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 13.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.18 |
EPS | $-12.25 |
Book Value | $26.51 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
